Format

Send to

Choose Destination
J Clin Apher. 2018 Oct;33(5):580-585. doi: 10.1002/jca.21644.

Therapeutic white blood cell and platelet depletions using the spectra OPTIA system continuous mononuclear cell protocol.

Author information

1
Therapeutic Apheresis Service, Duke University Medical Center, Durham, North Carolina.
2
Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

Abstract

The Spectra Optia apheresis system has only recently been approved by the Food and Drug Administration (FDA) for therapeutic white blood cell (WBC) depletions and is not yet approved for platelet depletions. Prior to FDA-approval of the WBC depletion protocol, when our available COBE Spectra apheresis systems were out of service, we successfully performed WBC depletion using a modified Spectra Optia apheresis system Continuous Mononuclear Cell (CMNC) protocol. Using this modified Spectra Optia CMNC protocol, we created institutional protocols for WBC and platelet depletions. We performed 10 WBC depletions in 9 patients and 2 platelet depletions in 2 patients. We compared pre- and post-procedure WBC, platelet count, and hemoglobin to the same data from patients previously treated on the COBE Spectra and found no difference in % WBC and platelet reduction. We also found no significant difference in post-procedural hematocrit decline. Additionally, adverse reactions were not increased. Therefore, we conclude that the Spectra Optia CMNC protocol can be successfully modified for effective WBC and platelet depletions without increase in adverse reactions.

KEYWORDS:

CMNC protocol; COBE spectra; leukapheresis; plateletpheresis

PMID:
30325054
DOI:
10.1002/jca.21644
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center